Method of Treating a Disorder of Cognitive Performance or Memory

Abstract

A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome.

I claim: 
     
         1 . A method of treating a disorder of cognitive performance or memory, comprising orally administering to a subject in need thereof a composition comprising:
 a. alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG); and   b. a lipase, a protease and an amylase.   
     
     
         2 . The method according to  claim 1 , wherein the composition comprises: 200-20000 USP units of lipase per mmol AKG, 500-50000 USP units of protease per mmol AKG and 200-20000 USP units of amylase per mmol AKG. 
     
     
         3 . The method according to  claim 2 , wherein the lipase is a  Burkholderia cepacia  lipase, preferably as cross-linked lipase crystals, the protease is an  Aspergillus melleus  protease and the amylase is an  Aspergillus oryzae  amylase. 
     
     
         4 . The method according to  claim 2 , wherein the lipase is a pancrelipase lipase, the protease is a pancrelipase protease and the amylase is a pancrelipase amylase. 
     
     
         5 . The method according to  claim 1 , said method comprising orally administering an amount of the composition containing about 12-240 mmol AKG to a subject per day. 
     
     
         6 . The method according to  claim 2 , said method comprising orally administering an amount of the composition containing about 12-240 mmol AKG to a subject per day. 
     
     
         7 . The method according to  claim 6 , said method comprising orally administering an amount of the composition containing about 24-120 mmol AKG to a subject per day. 
     
     
         8 . The method according to  claim 7 , said method comprising orally administering an amount of the composition containing about 36-120 mmol AKG to a subject per day. 
     
     
         9 . The method according to  claim 8 , said method comprising orally administering an amount of the composition containing about 60-120 mmol AKG to a subject per day. 
     
     
         10 . The method according to  claim 1 , said method comprising administering an amount of the composition containing 1-10 g AKG to a patient per day. 
     
     
         11 . The method according to  claim 2 , said method comprising administering an amount of the composition containing 1-10 g AKG to a patient per day. 
     
     
         12 . The method according to  claim 1 , being a method of treating a disorder of cognitive performance. 
     
     
         13 . The method according to  claim 1 , being a method of treating a disorder of memory. 
     
     
         14 . The method according to  claim 1 , wherein the disorder of cognitive performance or memory is mild cognitive impairment (MCI). 
     
     
         15 . The method according to  claim 8 , being a method of treating a disorder of cognitive performance. 
     
     
         16 . The method according to  claim 8 , being a method of treating a disorder of memory. 
     
     
         17 . The method according to  claim 1 , wherein the AKG comprises Ca-AKG, Na-AKG, ornithine-AKG, arginine AKG, or a combination thereof. 
     
     
         18 . The method according to  claim 1 , wherein the composition is administered encapsulated in a protective enteric coating. 
     
     
         19 . The method according to  claim 8 , wherein the composition is administered encapsulated in a protective enteric coating.